Form D · Pharmaceuticals

Athenen Therapeutics, Inc.

Boston, MA · CIK 0001790234

Offering snapshot reported Jul 31, 2020 · SEC filing

Reported sold
$12M
Offering amount: $15M
Investors reported
3
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 19, 2019
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$6M$12MOct 4, 2019: $5,000,001.00Oct 4, 2019Jul 31, 2020: $12,000,003.00Jul 31, 2020

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$5,000,001 → $12,000,003

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 31, 2020Amendment$12,000,003$7,000,002vs Oct 4, 20193SEC filing
Oct 4, 2019Initial$5,000,001No comparison3SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-350383

Source: Form D, filed Jul 31, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Aaron Bergener Executive
Sari Epstein Executive
Andrew Levin Director
Sarah Reed Executive
Joshua Resnick Director
Adam Rosenberg Director, Executive
James Schneider Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
200 Berkeley Street, 18 Th Floor C/O Ra Capital
Boston, MA, 02116